Michigan is currently home to 2174 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Ketamine Vs Lidocaine in Traumatic Rib Fractures
NCT04781673
Recruiting
Rib fractures continue to be a common occurrence in trauma patients of all ages. Traumatic rib fractures can cause severe pain in patients and lead to shallow breathing and further complications such as the need for mechanical ventilation, hospital or ventilator associated pneumonia, atelectasis, and acute respiratory distress syndrome. Effective multimodal pain management is needed to optimize a patient's respiratory status and can also play a role in early mobility, less pulmonary complication... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Spectrum Health Hospital, Grand Rapids, Michigan
Conditions: Rib Fractures, Rib Fracture Multiple, Rib Trauma
Register for Updates
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067
Recruiting
Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/16/2025
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Advanced or Metastatic NRAS-mutant Melanoma
Register for Updates
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06130566
Recruiting
This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for SC injection compared with placebo in participant... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
01/16/2025
Locations: Revival Research Institute - Dearborn- Site Number : 8401012, Dearborn, Michigan
Conditions: Dermatitis Atopic
Register for Updates
IC-8 Apthera IOL New Enrollment Post Approval Study
NCT06060041
Recruiting
The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
01/16/2025
Locations: Oakland Eye, Birmingham, Michigan
Conditions: Cataract, Presbyopia, Posterior Capsule Opacification
Register for Updates
Roux-en-Y Gastric Bypass Versus Loop Gastrojejunostomy for Malignant Gastric Outlet Obstruction
NCT05986890
Recruiting
This study is intended to investigate whether roux-en-y bypass surgery is superior to conventional loop gastrojejunostomy for Malignant gastric outlet obstruction in terms of tolerance to solid food intake. We hypothesize that roux-en-y bypass will be associated with improved solid food intake in the first 30 days after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: G. Paul Wright, Grand Rapids, Michigan
Conditions: Malignant Gastric Outlet Obstruction
Register for Updates
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
NCT05859464
Recruiting
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ZL-1218 as a single agent and as combination therapy in subjects with advanced solid tumor malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Zai Lab Site 2007, Detroit, Michigan
Conditions: Malignant Solid Tumor
Register for Updates
Trial of 225Ac-DOTATATE (RYZ101) in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857
Recruiting
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Research Facility, Detroit, Michigan
Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
Register for Updates
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared with Placebo in Adult Participants with Moderate to Severe Hidradenitis Suppurativa
NCT06411379
Recruiting
This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Clinical Site, Ann Arbor, Michigan
Conditions: Hidradenitis Suppurativa
Register for Updates
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
NCT06310031
Recruiting
The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/15/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Cardiovascular Diseases, Heart Diseases, Heart Failure
Register for Updates
Network Connectivity and Temporal Processing in Adolescents Who Stutter
NCT05286151
Recruiting
The specific purpose of this clinical trial is to compare performance on rhythm perception and production tasks between children who stutter and children who do not stutter. The overall project also aims to investigate how performance on rhythm tasks may be related to brain activity (non-clinical trial).
Gender:
ALL
Ages:
Between 9 years and 13 years
Trial Updated:
01/15/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Stuttering, Childhood, Stuttering
Register for Updates
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
NCT05249101
Recruiting
This study is a Phase 1b/2, dose-escalation, randomized, multicenter study to assess the efficacy, safety, tolerability, and PK of ivaltinostat in combination with capecitabine and capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on a first line fluoropyrimidine-based chemotherapy (e.g., FOLFIRINOX). In Phase 1b, 3 dose levels of ivaltinostat will be studied in combination with a fixed dose of capecitabine to determine the RP2D of i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Metastatic Pancreatic Adenocarcinoma
Register for Updates
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
NCT05038332
Recruiting
The primary purpose of this study is to compare the quality of life (QOL) reported by prostate cancer patients 2 years after treatment with ultra-hypofractionated post-prostatectomy radiation therapy (also known as stereotactic body radiation therapy \[SBRT\]) versus the self-reported QOL of those treated with moderately hypo-fractionated post-prostatectomy radiation (a current standard of care option).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Prostate Cancer
Register for Updates